Fundraising Foxi&i Biotech Fund — Full Portfolio
5 tracked investments · listed companies and verified rows first
Sophomer is a Czech biotech company developing in vitro diagnostics (IVD) products, working in partnership with academic labs on the design and synthesis of new polymers.
BiotechHealthtechMedical DevicesNew Materials
Martin Burkhard(Founder & Managing Director – CEO, Operations & Development)Jan Plicka(Founder and Inventor & Managing Director – R&D)Jiří Moos(Founder and Inventor & Managing Director, Business Development)inTomáš Etrych(Founder and Inventor & Sophomer's Partner Lab)Libor Kostka(Founder and Inventor & Sophomer's Partner Lab)Vladimír Šubr(Founder and Inventor & Sophomer's Partner Lab)
Co-investorsBiotech Investments S.R.O
Antiverse is a techbio company that uses machine learning and cell line engineering to design de novo antibody therapeutics against difficult targets such as G-protein coupled receptors and ion channels.
AI & Machine LearningBiotechDeep TechCardiff, GB
Ben H.(Founder)in
Co-investorsCambridge Angels groupDeep Science VenturesDOMiNO VenturesFuture Planet CapitalInnospark VenturesTensor Ventures+1 more
CasInvent Pharma develops pharmaceutical solutions, currently raising Series A funding through a crowdfunding campaign.
BiotechHealthtech
Alexander Scheer(CEO)in
Co-investorsBiotech Investments S.R.OJIC VenturesKhanu
Delta Development Team manufactures temperature-controlled medical transport and storage devices, including smart blood coolers and autonomous refrigeration units, for healthcare facilities and blood banks.
HardwareHealthtechLogistics & Supply ChainMedical Devices
Co-investorsAggie Angel NetworkAZ Venture Capital Inc.Central Texas Angel NetworkOost NL
Delta Life Science develops the inQuiQ, a label-free biosensing instrument that uses integrated photonics to measure biomolecular binding affinity and kinetics (KD, ka, kd) in real time from small sample volumes.
BiotechDeep TechHardware
Co-investorsOost NL
Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.
BiotechHealthtechBaltimore, US
Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)
BoardJonathan Leff(Director)Robert Jackson(Director)
Co-investorsBiotech Investments S.R.OOUP (Osage University Partners)Deerfield Management CompanySofinnova Ventures
Enzyre develops a handheld diagnostic device that performs multiple blood coagulation assays in parallel to identify bleeding causes at the point of care.
BiotechDeep TechDigital HealthHealthtechMedical DevicesEindhoven, NL
Wim van den Broek(CEO)inWaander(CSO)
Co-investorsNovalis BiotechOost NLTakeda Ventures
Heartbeat.bio develops cardiac chamber models (Cardioids) and an assay suite that characterize heart disease phenotypes at structural, functional, and molecular levels.
BiotechDeep TechHealthtech
iQure Pharma is a clinical-stage biotech developing astrocyte-targeted therapeutics that enhance EAAT2 to restore glutamate balance in central nervous system disorders such as epilepsy, Parkinson's disease, migraine, and ALS.
BiotechHealthtechSkillman, US
Peter Schiemann(Founder)inPawel Zolnierczyk(Executive Officer)in
Co-investorsKeiretsu ForumVentura BioMed Investors
KyDo Therapeutics is a preclinical-stage biotechnology company developing novel covalent-allosteric small molecule inhibitors intended to become best-in-class oncology drugs.
AI & Machine LearningBiotechDortmund, DE
Co-investorsKhanu
LAM-X develops advanced nanofiber and polymer materials, including light-activated antimicrobial textiles and Western Blot membranes, for applications in medical devices, food packaging, crop protection, water filtration, and life science research.
BiotechMedical DevicesNew MaterialsZlatníky-Hodkovice, CZ
Nanoligent is a biotech spin-off of the Universitat Autònoma de Barcelona and Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau that uses protein engineering and nanobiotechnology to develop targeted drug therapies, with a first cancer candidate targeting the CXCR4 receptor to limit tumor growth and metastasis.
BiotechDeep TechMedical DevicesBarcelona, ES
Dr. A. Villaverde(Founder)Dr. E. Vázquez(Founder)Dr. R. Mangues(Founder)Dr. M. Rodríguez(Founder)
Co-investorsItalian Angels for Growth
Sampling Human develops systems to generate actionable insights from individual biology using cellular-resolution data collection technologies.
AI & Machine LearningBiotechHealthtech
Daniel Georgiev(Co-Founder, CEO, and Board Member)inHynek Kasl(Co-Founder and Head of Engineering)inMartin Cienciala(Co-Founder and Head of Innovation)in
Co-investorsB3 HoldingBiotech Investments S.R.O
T-CURX is a venture-backed biotechnology company developing autologous CAR-T cell therapies using proprietary non-viral technologies, including in vivo and bedside-manufactured CAR-T approaches based on T cell-targeted LNP delivery of Sleeping Beauty transposon vectors.
BiotechHealthtechWürzburg, DE
Michael Hudecek(Co-founder)Christoph Rader(Co-founder & Member of the Scientific Advisory Board)Ulf Grawunder(Co-founder & CEO)in
Co-investorsHighlight CapitalBioMedPartners
Ternary develops AI-driven drug discovery technology focused on targeted protein degradation and induced proximity platforms.
AI & Machine LearningBiotechDeep Tech
Chris Tame(CEO & Co-Founder)inAndrew Potterton(CTO & Co-Founder)in
Co-investorsDaphniPace VenturesUK Innovation & Science Seed Fund
Vasa Therapeutics is a biopharmaceutical company focused on discovering and developing therapeutics that target the pathophysiology of cardiovascular aging.
BiotechLongevity
Co-investorsNuFund Venture Group
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Captain T Cell GmbHCeleris Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.